摘要
目的探讨三阴乳腺癌对含蒽环类方案新辅助化疗的价值。方法方便收集2015年1月—2016年4月该院100例乳腺癌患者,根据雌激素受体,孕激素受体、人表皮生长因子受体-2表达情况,分为50例研究组(三阴乳腺癌)和50例对照组(非三阴乳腺癌)。研究组和对照组给予含蒽环类新辅助化疗:(环磷酰胺500 mg/m2,吡喃阿霉素50 mg/m2,5-氟脲嘧啶500 mg/m2),新辅助化疗后20 d进行手术切除乳腺癌病灶,术后2周给予常规化疗(多西他赛75 mg/m2、顺铂50 mg/m2)。对比两组治疗后临床疗效;两组无疾病进展生存期、缓解期及总生存期。结果研究组和对照组治疗后临床反应分别为78%(39/50)、60%(31/50),比较差异有统计学意义(χ2=7.52,P<0.05);研究组无疾病进展生存期、缓解期及总生存期明显长于对照组,两组分别为(13.25±3.26)个月、(17.34±3.11)个月、(25.64±4.25)个月、(11.74±4.82)个月、(15.34±3.52)个月、(20.13±3.14)个月,比较差异有统计学意义(t=5.29、6.33、7.15,P<0.05)。结论三阴乳腺癌对含蒽环类药物方案新辅助化疗疗效敏感,治疗后能够延长患者生存期。
Objective To investigate the value of triple-negative breast cancer in neoadjuvant chemotherapy for anthracycline-containing regimens. Methods 100 patients with breast cancer were conveniently enrolled in our hospital from January 2015 to April 2016. According to the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2, 50 patients in the study group (three Yin breast cancer) and 50 control group (non-three-negative breast cancer). The study group and the control group were given neoadjuvant chemotherapy with anthracycline:(cyclophosphamide 500 mg/m^2, pirarubicin 50 mg/m^2, 5-fluorouracil 500 mg/m^2), surgical resection 20 days after neoadjuvant chemotherapy breast cancer lesions, conventional chemotherapy (docetaxel 75 mg/m^2, cisplatin 50 mg/m^2) was given 2 weeks after surgery. The clinical efficacy of the two groups after treatment was compared;the two groups had no disease progression, survival, remission and overall survival. Results The clinical response of the study group and the control group were 78%(39/50) and 60%(31/50), respectively. the different was statistically significant(χ^2=7.52, P<0.05). The study group had no disease progression and survival. The remission period and overall survival were significantly longer than the control group, and the two groups were (13.25±3.26)months,(17.34±3.11)months,(25.64±4.25)months,(11.74±4.82)months,(15.34±3.52)months,(20.13±3.14)months. the different was statistically significant(t=5.29, 6.33, 7.15, P<0.05). Conclusion Sanyin breast cancer is sensitive to neoadjuvant chemotherapy with anthracycline-containing regimen, and can prolong the survival of patients after treatment.
作者
苗盼
MIAO Pan(Department of Vein Dispensing, Qilu Hospital of Shandong University, Jinan, Shandong Province, 250012 China)
出处
《中外医疗》
2019年第3期120-122,共3页
China & Foreign Medical Treatment
关键词
三阴
乳腺癌
蒽环
化疗
Sanyin
Breast cancer
Ankle ring
Chemotherapy
